Through the collaborative efforts of the Saskatchewan Cancer Agency, the Government of Saskatchewan including the Saskatchewan Disease Control Laboratory, the Regina Qu'Appelle Health Region and Phenomenome Discoveries Inc., a clinical trial began in June 2008 to assess the efficacy of the gTA test compared to colonscopy as a screening test for colorectal cancer.
The primary trial goal is to evaluate the predictive power of gTA levels as a pre-colonoscopy screening procedure. This is a non-randomized, multi-center prospective cohort study taking place over a two year period. Our goal is to enroll a minimum of 5000 subjects.
The trial is taking place in Regina at the Pasqua and General Hospitals.
All patients scheduled for colonoscopy at one of the two sites will be asked to participate. These volunteers will be asked to donate two serum samples, one on the day of colonoscopy and one 14 days following. The samples will be analyzed at the Saskatchewan Disease Control Laboratory. The gTA test score will then be compared to colonoscopy and pathology results.
This trial is approved by the University of Saskatchewan Ethics Committee (protocol #Bio:07-199), and by the Regina Qu'Appelle Health Region Research Ethics Committee (project # REB-08-06).
See our news page for press release and media coverage of the announcement and results of this trial, which concluded in 2010.
For Media - Trial Informational Backgrounder